Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Pre-Tax Margin for the quarter ending September 30, 2023: -238,900.00%

Freeline Therapeutics Holdings Plc Pre-Tax Margin is -238,900.00% for the quarter ending September 30, 2023. Pre-tax margin represents the proportion of a company's earnings before taxes (EBT) to its revenue. It is calculated by dividing the EBT by the revenue. This ratio indicates the profitability of the company's operations before the impact of taxes. A higher pre-tax margin suggests that the company generates a larger proportion of revenue as pre-tax profit, indicating stronger operational performance and efficiency.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email